Fortrea Holdings Inc.
FTREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Fortrea Holdings Inc. (FTRE) is listed under Biotechnology. With a market capitalization of $1.42B, it sits in small-cap territory. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Market Cap
$1.42B
Beta
1.91
P/E (TTM)
—
P/E (Fwd)
13.93
EPS (TTM)
$-4.81
EPS (Fwd)
$1.08
ROE
-64.5%
ROA
-0.1%
Cash
$147.5M
Total Debt
$1.12B
Free CF
$285.6M
52W Change
248.8%
Annual Financials
Cash vs Debt
The company holds $147.5M in cash, though total debt stands at $1.12B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $285.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -64.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $3.06B to $2.72B.
With a beta above 1.5, FTRE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Fortrea Holdings Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fortrea Holdings Inc. and its sector.